Hanna Taipaleenmäki

20PUBLICATIONS
52CO-AUTHORS
HaematologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jun 16, 2026
Complement factor H (CFH), an immune factor enhances osteoblast differentiation and correlates with bone density.

|Jun 11, 2026
Bone-derived Osterix+ osteolineage cells are a source of tumor-promoting myofibroblastic cancer-associated fibroblasts in breast cancer.

|May 14, 2026
The endosteal niche regulates breast cancer cell dormancy in bone: identification of new molecular determinants.

|Dec 15, 2025
Therapeutic Management of Glucocorticoid-Induced Osteoporosis with a Focus on Older Adults: A Narrative Review.

Elena Tsourdi, Ulrike Baschant, Martina Rauner

|Aug 14, 2025
Tgif1-deficiency impairs osteoclast differentiation through PP2A-mediated ERK1/2 dephosphorylation and attenuates bone loss in mice.

Miki Maeda, Hiroaki Saito, Amy B P Ribet

|Aug 06, 2025
Bone anabolic therapy in breast cancer: is there a role for parathyroid hormone or parathyroid hormone-related protein?

Hanna Taipaleenmäki, Matthew T Drake

Pageof 4

Frequent Collaborators

4 joint publications

Eric Hesse

3 joint publications

Daniel J Smit

2 joint publications

Christina Møller Andreasen

2 joint publications

Martina Rauner